<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03432299</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-RFA-PTMC</org_study_id>
    <nct_id>NCT03432299</nct_id>
  </id_info>
  <brief_title>Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma</brief_title>
  <acronym>RFAforPTMC</acronym>
  <official_title>Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma: Safety and Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center prospective clinical trial with regard to efficacy and safety of&#xD;
      radiofrequency ablation of papillary thyroid microcarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For treatment of papillary thyroid microcarcinoma (PTMC), radiofrequency ablation (RFA) will&#xD;
      be performed with the supine position and neck extended under ultrasonogrphic guidance.&#xD;
      Before RFA, local anesthesia will be performed. RFA system including radiofrequency generator&#xD;
      (VIVA RF system, STARmed, Goyang-si, Korea) and internally cooled electrode (star RF&#xD;
      electrode, STARmed, Goyang-si, Korea) will be used. With regard to RFA procedure, moving shot&#xD;
      technique and hydrodissection, if indicated, will be used. After RFA, follow-up will be&#xD;
      performed using ultrasonography, serum thyroid function test, and questionnaire for quality&#xD;
      of life by face-to-face interview at 2 months, 6, 12, 18, 24 months during the first 2 years&#xD;
      after RFA, and yearly afterwards.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 16, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of tumor size</measure>
    <time_frame>baseline, 2, 6, 12, 18, 24 months during the first two years after RFA, and yearly afterwards upto 10 years</time_frame>
    <description>Maximal dimension (mm) of ablation zone on Ultrasonography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of Metastasis</measure>
    <time_frame>baseline, 2, 6, 12, 18, 24 months during the first two years after RFA, and yearly afterwards upto 10 years</time_frame>
    <description>Cervical Lymph node metastasis on Ultrasonography or other distant metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Quality of Life</measure>
    <time_frame>baseline, 2, 6, 12, 18, 24 months during the first two years after RFA, and yearly afterwards upto 10 years</time_frame>
    <description>Score on a Korean version of a thyroid-specific Quality-of-life Questionnaire Scale in Thyroid Cancer Patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of potential side effects from RFA</measure>
    <time_frame>baseline, 2, 6, 12, 18, 24 months during the first two years after RFA, and yearly afterwards upto 10 years</time_frame>
    <description>rate of patients who underwent potential side effects from RFA</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Papillary Thyroid Microcarcinoma</condition>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>RFA for PTMC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group who will undergo RFA after diagnosis of PTC</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RFA for PTMC</intervention_name>
    <description>Radiofequency ablation for papillary thyroid microcarcinoma will be performed using the system including radiofrequency generator and internally cooled electrode.</description>
    <arm_group_label>RFA for PTMC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  who agrees to the consent form&#xD;
&#xD;
          -  aged from 19 to 60 years old&#xD;
&#xD;
          -  who has been diagnosed with Bethesda category V or VI by fine needle aspiration or&#xD;
             needle biopsy&#xD;
&#xD;
          -  whose thyroid cancer is 1 cm or smaller than 1 cm length&#xD;
&#xD;
          -  who does not have lymph node or distant metastasis&#xD;
&#xD;
          -  whose thyroid cancer does not have extrathyroidal extension&#xD;
&#xD;
          -  in whom it seems technically possible to completely ablate thyroid cancer using RF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  who cannot routinely followed up according to the study schedule&#xD;
&#xD;
          -  who has been with Bethesda category I, II, III, or IV by fine needle aspiration or&#xD;
             needle biopsy.&#xD;
&#xD;
          -  who has hyperthyroidism that requires treatment&#xD;
&#xD;
          -  who has bleeding tendency&#xD;
&#xD;
          -  multifocal papillary thyroid microcarcinoma&#xD;
&#xD;
          -  who is pregnant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji-hoon Kim, MD,Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ji-hoon Kim, MD,Ph.D</last_name>
    <phone>+82-2-2072-3280</phone>
    <email>jihnkim@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 22, 2018</study_first_submitted>
  <study_first_submitted_qc>February 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Ji-hoon Kim</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Thyroid Diseases</keyword>
  <keyword>Radiofrequency Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Papillary</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

